Screening of potential antiviral molecules against equid herpesvirus-1 using cellular impedance measurement: Dataset of 2,891 compounds

Abstract

Data presented in this article are associated with the research article "Identification of antiviral compounds against equid herpesvirus-1 using real-time cell assay screening: efficacy of decitabine and valganciclovir alone and in combination" [1]. These data correspond to the in vitro screening of 2,891 potential antiviral compounds against equid herpesvirus-1 (EHV-1) based on impedance measurements using the xCELLigence® RTCA MP System. This dataset includes compounds from three different libraries: i) 1,199 compounds from the Prestwick® Chemical Library, which contains mostly US Food and Drug Administration approved drugs (Prestwick® Chemical, Illkirch, France); ii) 1,651 compounds from the Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN, Caen, France); iii) 41 compounds (called herein in-house antiviral library) selected for their effects against different human viruses. Compounds effective against EHV-1 were selected using the area under normalised curves (AUC_n) and the time required for the Cell Index to decrease by 50% after virus infection (CIT₅₀). The full dataset from the screen is made publicly available for further analyses.

Keywords: Antiviral; Chemical library screening; Equid herpesvirus-1; Real-time cell assay.

Fig. 1

Dataset screening of 2,891 chemical compounds from three libraries to identify EHV-1 inhibitors. The CERMN library (A, B) was screened at 10 µM, Prestwick® Chemical library (C, D) at 10 µg/mL and in-house antiviral library (E, F) at 4 concentrations (0.4, 2, 10 and 50 µM). The percentage of area under normalised Cell Index (CI) from 0 to 96 hpi of treated cells compared to mock-treated cells (%AUC_n) were reported graphically for each library. The red line represents the cut-off 25 % from which compound could identified as potential antiviral compounds against EHV-1 (A, C, E). The increase of the time required for the CI to decrease by 50 % after virus infection (CIT₅₀) of treated cells compared to mock-treated cells (ΔCIT₅₀) were reported graphically for each library. The red line represents the cut-off 8 h of delay from which compound could identified as potential antiviral compounds against EHV-1 (B, D, F). The original figure can be found online in Supplementary figure 1 ([1]) at https://doi.org/10.1016/j.antiviral.2020.104931.